ERBB2 exon 20 insertion accounts for 2-3% of the total mutations of non-small cell lung cancer. However, there is still an unmet need for treating patients with this kind of mutation. The phase 2 ZENITH20 trial is aimed to study the activity of poziotinib in NSCLC patients with either an EGFR exon 20 insertion or an ERBB2 exon 20 insertion.
